PL2758060T3 - Modulatory ROR-gamma do leczenia powikłań cukrzycy typu II - Google Patents
Modulatory ROR-gamma do leczenia powikłań cukrzycy typu IIInfo
- Publication number
- PL2758060T3 PL2758060T3 PL12759466T PL12759466T PL2758060T3 PL 2758060 T3 PL2758060 T3 PL 2758060T3 PL 12759466 T PL12759466 T PL 12759466T PL 12759466 T PL12759466 T PL 12759466T PL 2758060 T3 PL2758060 T3 PL 2758060T3
- Authority
- PL
- Poland
- Prior art keywords
- complications
- treating diabetes
- ror gamma
- gamma modulators
- modulators
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11007610 | 2011-09-19 | ||
| PCT/EP2012/068332 WO2013041519A1 (en) | 2011-09-19 | 2012-09-18 | Ror gamma modulators |
| EP12759466.1A EP2758060B1 (en) | 2011-09-19 | 2012-09-18 | Ror gamma modulators for treating diabetes ii complications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2758060T3 true PL2758060T3 (pl) | 2018-04-30 |
Family
ID=46852019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12759466T PL2758060T3 (pl) | 2011-09-19 | 2012-09-18 | Modulatory ROR-gamma do leczenia powikłań cukrzycy typu II |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9777036B2 (pl) |
| EP (1) | EP2758060B1 (pl) |
| JP (2) | JP2014526494A (pl) |
| KR (1) | KR102020923B1 (pl) |
| CN (1) | CN103957919B (pl) |
| AU (1) | AU2012311599B2 (pl) |
| BR (1) | BR112014003704A2 (pl) |
| DK (1) | DK2758060T3 (pl) |
| ES (1) | ES2659455T3 (pl) |
| NO (1) | NO2758060T3 (pl) |
| PL (1) | PL2758060T3 (pl) |
| PT (1) | PT2758060T (pl) |
| RU (1) | RU2658013C2 (pl) |
| WO (1) | WO2013041519A1 (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013169864A2 (en) | 2012-05-08 | 2013-11-14 | Lycera Corporation | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE |
| CN104603118B (zh) | 2012-05-31 | 2017-10-03 | 菲尼克斯药品股份公司 | 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物 |
| JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
| EP2781217A1 (en) * | 2013-03-18 | 2014-09-24 | ETH Zurich | ROR gamma modulators |
| CA2922501A1 (en) * | 2013-09-11 | 2015-03-19 | F. Hoffmann-La Roche Ag | Keto-imidazopyridine derivatives as rorc modulators |
| CN105829316B (zh) * | 2013-12-19 | 2019-01-08 | 默克专利股份公司 | 作为RORγ抑制剂的四氢-四唑并[1，5-a]吡嗪 |
| JP2017507950A (ja) | 2014-02-27 | 2017-03-23 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法 |
| WO2015171558A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE |
| CA2947290A1 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| WO2016179343A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE |
| MX2017016134A (es) | 2015-06-11 | 2018-08-15 | Lycera Corp | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. |
| ES2928904T3 (es) * | 2016-10-27 | 2022-11-23 | Escalier Biosciences Bv | Moduladores de ROR-gamma |
| EP3662076A2 (en) | 2017-08-03 | 2020-06-10 | Vio Chemicals AG | Method for preparing bile acid compound via enzymatic catalysis |
| CN109912676B (zh) * | 2019-03-07 | 2021-08-27 | 上海科骊科生物技术有限公司 | 一种3β-熊去氧胆酸的制备方法 |
| WO2022233398A1 (en) | 2021-05-04 | 2022-11-10 | Kostner Pharma Gmbh | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07126283A (ja) * | 1993-09-03 | 1995-05-16 | Kunio Tsuji | 胆汁アルコール |
| EP0832094B1 (en) | 1995-06-07 | 2004-02-11 | Genaera Corporation | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (nhe), pharmaceutical methods and compositions employing such inhibitors, and processes for evaluating the nhe-inhibitory efficacy of compounds |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| JP2000026300A (ja) | 1998-07-02 | 2000-01-25 | Pola Chem Ind Inc | 血管内皮細胞保護医薬組成物 |
| AU780658B2 (en) | 1999-03-26 | 2005-04-07 | City Of Hope | Method of affecting cholesterol catabolism using nuclear bile acid receptor |
| EP1219294A4 (en) | 1999-09-20 | 2005-01-26 | ANTAGONISTS OF THE MELANIN CONCENTRATING HORMON | |
| WO2001021577A2 (en) | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| CA2406930C (en) * | 2000-02-04 | 2011-02-15 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| BRPI0109200B8 (pt) | 2000-03-14 | 2021-05-25 | Actelion Pharmaceuticals Ltd | compostos e composições farmacêuticas |
| PT1289955E (pt) | 2000-06-16 | 2005-08-31 | Smithkline Beecham Plc | Piperidinas para utilizacao como antagonistas dos receptores da orexina |
| WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| WO2004000869A1 (en) * | 2002-06-19 | 2003-12-31 | Karo Bio Ab | Glucocorticoid receptor ligands for the treatment of metabolic disorders |
| US20090074895A1 (en) * | 2005-05-02 | 2009-03-19 | Vanadis Bioscience Ltd | Composition and uses thereof |
| CN101679476B (zh) | 2007-01-19 | 2014-05-07 | 英特塞普特医药品公司 | 23取代的胆汁酸作为tgr5调节剂及其使用方法 |
| WO2009011420A1 (ja) * | 2007-07-18 | 2009-01-22 | Mitsubishi Tanabe Pharma Corporation | ２型糖尿病の治療薬 |
| CA2716922C (en) * | 2008-02-26 | 2016-06-28 | British Columbia Cancer Agency Branch | Polyhydroxylated bile acids for treatment of biliary disorders |
| AU2010286253A1 (en) * | 2009-08-25 | 2012-04-19 | Victor Ling | Polyhydroxylated bile acids for treatment of biliary disorders |
-
2012
- 2012-09-18 RU RU2014115796A patent/RU2658013C2/ru not_active IP Right Cessation
- 2012-09-18 KR KR1020147010403A patent/KR102020923B1/ko active IP Right Grant
- 2012-09-18 US US14/345,597 patent/US9777036B2/en active Active
- 2012-09-18 PL PL12759466T patent/PL2758060T3/pl unknown
- 2012-09-18 WO PCT/EP2012/068332 patent/WO2013041519A1/en active Application Filing
- 2012-09-18 JP JP2014530269A patent/JP2014526494A/ja active Pending
- 2012-09-18 DK DK12759466.1T patent/DK2758060T3/en active
- 2012-09-18 NO NO12759466A patent/NO2758060T3/no unknown
- 2012-09-18 EP EP12759466.1A patent/EP2758060B1/en active Active
- 2012-09-18 AU AU2012311599A patent/AU2012311599B2/en not_active Ceased
- 2012-09-18 ES ES12759466.1T patent/ES2659455T3/es active Active
- 2012-09-18 PT PT127594661T patent/PT2758060T/pt unknown
- 2012-09-18 CN CN201280045611.7A patent/CN103957919B/zh not_active Expired - Fee Related
- 2012-09-18 BR BR112014003704A patent/BR112014003704A2/pt not_active Application Discontinuation
-
2017
- 2017-07-28 JP JP2017146926A patent/JP6439206B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140079416A (ko) | 2014-06-26 |
| NO2758060T3 (pl) | 2018-04-28 |
| BR112014003704A2 (pt) | 2017-03-07 |
| WO2013041519A9 (en) | 2013-06-27 |
| US9777036B2 (en) | 2017-10-03 |
| EP2758060B1 (en) | 2017-11-29 |
| PT2758060T (pt) | 2018-01-24 |
| AU2012311599A1 (en) | 2014-02-20 |
| CN103957919A (zh) | 2014-07-30 |
| WO2013041519A1 (en) | 2013-03-28 |
| NZ620485A (en) | 2016-04-29 |
| ES2659455T3 (es) | 2018-03-15 |
| CN103957919B (zh) | 2018-10-16 |
| RU2658013C2 (ru) | 2018-06-19 |
| JP2014526494A (ja) | 2014-10-06 |
| RU2014115796A (ru) | 2015-10-27 |
| DK2758060T3 (en) | 2018-03-05 |
| AU2012311599B2 (en) | 2017-07-06 |
| JP6439206B2 (ja) | 2018-12-19 |
| KR102020923B1 (ko) | 2019-09-11 |
| JP2018024651A (ja) | 2018-02-15 |
| US20140343023A1 (en) | 2014-11-20 |
| EP2758060A1 (en) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2758060T (pt) | Moduladores de ror gama para o tratamento de complicações de diabetes ii | |
| HK1244888A1 (zh) | 電光顯示器 | |
| IL231741A0 (en) | A modulator device with a configuration for implantation | |
| IL238742A0 (en) | Pyrrolidine as modulators of gpr40 | |
| EP2695019A4 (en) | ELECTROCHROMIC DEVICE | |
| EP2694053A4 (en) | SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF DIABETES | |
| GB201114439D0 (en) | Display device control | |
| EP2725084A4 (en) | LIQUID CRYSTAL COMPOSITION | |
| IL238780A0 (en) | Dihydropyrazole as modulators of gpr40 | |
| IL238741A0 (en) | Dihydropyrazole as modulators of grp40 | |
| IL238779A0 (en) | Dihydropyrazole as modulators of gpr40 | |
| EP2662593A4 (en) | Meshing chain stopper | |
| EP2927301A4 (en) | LIQUID CRYSTAL COMPOSITION | |
| EP2811005A4 (en) | LIQUID CRYSTAL COMPOSITION | |
| SG11201400772WA (en) | Backlight device | |
| EP2774917A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | |
| GB201108481D0 (en) | Electro-optic modulator | |
| EP2700698A4 (en) | LIQUID CRYSTAL COMPOSITION | |
| IL232566A0 (en) | Diabetes treatments using isoxazole | |
| EP2691148A4 (en) | ELECTRON TRANSPORT DEVICE CONSISTING OF TWO PARTS | |
| EP2773202A4 (en) | MODULATORS OF GAMMA-SECRETASE | |
| HRP20181375T1 (hr) | Novi kristalni oblici | |
| EP2883960A4 (en) | PROCESS FOR PRODUCING GLUTAMYL-VALYL-GLYCINE CRYSTAL | |
| EP2806012A4 (en) | LIQUID CRYSTAL COMPOSITION | |
| GB2512239B (en) | Display backlight modulation |